<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493181</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0113</org_study_id>
    <nct_id>NCT00493181</nct_id>
  </id_info>
  <brief_title>Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients</brief_title>
  <official_title>The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out if IL-11 (NeumegaTM) may increase the
      platelet count in patients with Chronic myeloid leukemia (CML) who develop low platelet
      counts while receiving therapy with imatinib mesylate (Gleevec, STI571), or other tyrosine
      kinase inhibitors such as AMN107, dasatinib, or SK1606.

      Primary Objective:

      1. To determine efficacy of low-dose interleukin-11, (IL-11, oprelvekin, NeumegaTM) in
      improving the thrombocytopenia associate with imatinib or other tyrosine kinase inhibitor
      therapy in patients with CML.

      Secondary Objective:

      1. To determine the safety of low-dose IL-11 in patients with CML and thrombocytopenia
      associated with imatinib or other tyrosine kinase inhibitors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IL-11 is a hormone normally produced in your body that plays a role in stimulating the
      production of platelets.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests&quot;. These tests will help the doctor decide if you are eligible to take part in the
      study. You will have a blood sample (1 teaspoon) collected to check your platelet count.
      Women who are able to have children must have a negative blood pregnancy test.

      If you are found to be eligible to take part in this study, you will receive one injection of
      IL-11 under the skin (usually of the arms, legs or abdomen) 3 times a week. If your platelet
      count increases, treatment will continue on this schedule as long as a platelet increase is
      observed. If the treatment is well tolerated but there is not enough of a platelet
      improvement, the dose and frequency of IL-11 injections may be increased. If the platelet
      count becomes high enough, treatment may be stopped but may also be restarted if necessary.

      During therapy with IL-11, additional blood samples (1 teaspoon each) will be collected to
      measure the platelet count every week until the platelets are stable and then every 2 to 6
      weeks while you are receiving treatment on study. No other tests are required for this study.

      While you are on this study, you will continue your treatment with imatinib mesylate or other
      tyrosine kinase inhibitor as decided by your doctor for standard care.You will be taken off
      if there is no response to treatment or if there are unacceptable side effects. There will be
      no follow-up after you go off study.

      This is an investigational study. The Food and Drug Administration (FDA) has approved IL-11
      for use in chemotherapy-caused low platelet counts. A maximum of 30 patients will take part
      in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response</measure>
    <time_frame>Weekly platelet count till stabilized with on-going review while receiving treatment (study total 2 years)</time_frame>
    <description>Number of participants with platelet response of 'Complete Response' (CR) defined as a sustained (&gt;/= 3 months) platelet count &gt;/= 60 x 10^9/L while continuing tyrosine kinase inhibitor (TKI) therapy or sustained (&gt;/= 3 months) re-escalation of TKI dose to the pre-thrombocytopenia level without recurrence of thrombocytopenia.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Interleukin-11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose 10 mcg/kg subcutaneously 3 times a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-11 (IL-11 or Neumega)</intervention_name>
    <description>10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.</description>
    <arm_group_label>Interleukin-11</arm_group_label>
    <other_name>IL-11</other_name>
    <other_name>Neumega</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CML patients in chronic or accelerated phase receiving treatment with imatinib
             mesylate (Gleevec), or other tyrosine kinase inhibitors such as AMN107, dasatinib, or
             SK1606.

          -  Grade &gt;/= 3 thrombocytopenia (platelets &lt;50 * 10(9)/L) after the first 4 weeks of
             therapy with the tyrosine kinase inhibitor. Thrombocytopenia must be either recurrent
             (i.e., second or greater episode of grade &gt;/= 3 thrombocytopenia) or having required
             dose reductions of the tyrosine kinase inhibitor.

          -  Signed informed consent.

          -  Expected to have therapy with imatinib continued for &gt; 3 months.

        Exclusion Criteria:

          -  Known allergies to E. coli.

          -  New York Heart Association (NYHA) class III or IV.

          -  Patient has known hypersensitivity to Neumega or any component of Neumega.

          -  Thrombocytopenia that is considered to be unrelated to treatment with imatinib.

          -  Stem cell transplantation within 60 days.

          -  History of atrial arrhythmias

          -  Pregnancy

          -  Papilledema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge E. Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's Website</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <results_first_submitted>April 1, 2011</results_first_submitted>
  <results_first_submitted_qc>April 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2011</results_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oprelvekin</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Imatinib</keyword>
  <keyword>IL-11</keyword>
  <keyword>Interleukin 11</keyword>
  <keyword>Neumega</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oprelvekin</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 10/15/05 to 9/17/07. All participants registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Interleukin-11</title>
          <description>Starting dose 10 mcg/kg subcutaneously 3 times a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interleukin-11</title>
          <description>Starting dose 10 mcg/kg subcutaneously 3 times a week</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="31" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response</title>
        <description>Number of participants with platelet response of 'Complete Response' (CR) defined as a sustained (&gt;/= 3 months) platelet count &gt;/= 60 x 10^9/L while continuing tyrosine kinase inhibitor (TKI) therapy or sustained (&gt;/= 3 months) re-escalation of TKI dose to the pre-thrombocytopenia level without recurrence of thrombocytopenia.</description>
        <time_frame>Weekly platelet count till stabilized with on-going review while receiving treatment (study total 2 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interleukin-11</title>
            <description>Starting dose 10 mcg/kg subcutaneously 3 times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response</title>
          <description>Number of participants with platelet response of 'Complete Response' (CR) defined as a sustained (&gt;/= 3 months) platelet count &gt;/= 60 x 10^9/L while continuing tyrosine kinase inhibitor (TKI) therapy or sustained (&gt;/= 3 months) re-escalation of TKI dose to the pre-thrombocytopenia level without recurrence of thrombocytopenia.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Interleukin-11</title>
          <description>Starting dose 10 mcg/kg subcutaneously 3 times a week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes M.D./Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713/794-5783</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

